ASKA Pharmaceutical Co. Ltd. Released New Drug According to BAC Company Report

04 Apr 2012 • by Natalie Aster

LONDON – In 2011 ASKA Pharmaceutical released the first Japanese the first emergency contraceptive – tablets named NorLevo® 0.75mg. The drug is used to avoid undesirable pregnancy and should be taken within 72 hours after the coitus. Principle of operation is based on synthetic analog of female hormone progesterone – levonorgestrel.

The drug is recognized in around 50 world countries to the date. After its launch in Japan ASKA Pharmaceutical took responsibility to provide full pharmaceutical information about it to distributors, as well as promote proper use of it among women.

ASKA Pharmaceutical has not been very successful in its financials recently. FY 2010/11 ended with negative outcome, and the one coming also seems to be inefficient. December 2011 returned revenues of JPY 11.4 B, gross profit of JPY 4.9 B, operating income of JPY 770 M, and net income of JPY 226 M. It is obviously not the strongest quarter for ASKA.

The financial forecast for the six months ending March 2012 gives positive net income (JPY 80 M), and cumulative value for all quarters is also expected to be positive (JPY 166 M) despite poor results of September 2011 (JPY (1.4) B). Revenues for the financial year ending March 2012 are projected at JPY 40 B, and operating income will amount JPY 748 M. This reflects revenue decrease and incomes increase over FY 2010/11, which is a sign of ASKA financial recovery.

Formed in 2005 and headquartered in Tokyo (Japan), ASKA Pharmaceutical Co Ltd engages in research, development and production of pharmaceuticals. Company’s products cover painkillers, analgesics, antipyretic components, natural vitamin E, gastritis treatment, prostate cancer drugs, antihyperlipidemic agents, chemoprotectants, follicle-stimulating hormone, among human medicals. The company also manufactures animal drugs: breeding medicine, drugs for digestion system, metabolic drugs, antiseptics, anti-fungal antibiotics, general antibiotics. There are also specified product lines for marine animals, feed nutrients, and skin care products.

Get more details on the company’s activities, risks, opportunities and forecasts from the report "ASKA Pharmaceutical Co.Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis" recently published by Market Publishers Ltd.

Report Details:

Title: ASKA Pharmaceutical Co.Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Date: Mar, 2012
Pages: 91

More company reports featuring SWOT and financial information, industry and competitors analysis can be found in Company Reports Catalog.



The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970